CD2BP2-DT

Across TCGA pan-cancer cohorts, CD2BP2-DT RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CD2BP2-DT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CD2BP2-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CD2BP2-DT is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

KIRC, KIRP, and LIHC are the cancer types where CD2BP2-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD2BP2-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	+1.056	<.001	12	view →
KIRP	All	II,III,IV	+1.117	<.001	11	view →
LIHC	Male	II,III,IV	+0.871	<.001	9	view →
HNSC	Male	III,IV	+0.848	<.001	8	view →
KICH	Male	All	−0.916	<.001	7	view →
BRCA	All	III,IV	+1.246	<.001	6	view →
BLCA	All	III,IV	+1.197	.001	6	view →
STAD	Male	II,III,IV	+1.080	<.001	4	view →
CHOL	All	All	+1.141	<.001	3	view →
PAAD	All	All	+0.555	.041	2	view →
LUSC	All	III,IV	−0.599	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CD2BP2-DT–KIRC

Open the KIRC breakdown →